3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
33
Nivolumab
15
atezolizumab
9
Cyclophosphamide
7
Paclitaxel
6
Ipilimumab
6
spartalizumab
5
fludarabine
5
Docetaxel
5
durvalumab
4
avelumab
4
Immune Checkpoint Inhibitors
4
Carboplatin
4
olaparib
3
cemiplimab
3
cabozantinib
3
Specimen Handling
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Interleukin-2
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
sacituzumab govitecan
2
obinutuzumab
2
lenvatinib
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
IPI-549
×
Genitourinary
×
Clear all
NCT03961698
2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2
Unknown
91 enrolled